An oral inflammatory bowel disease treatment would change daily life for many patients who now rely on injections or infusions, which is why Gilead’s Phase 2 result for emvistegrast in ulcerative colitis has drawn attention. On 19 October 2026 the company reported that its once-daily pill met the primary endpoint in the SWIFT study, with 66% of people on the 200 mg dose showing a clinical response at week 12 versus 37% on placebo. This explainer describes what the study measured, how to read the numbers, and what remains unproven. It is not medical advice.
Oral inflammatory bowel disease treatment: key takeaways
- Emvistegrast is an investigational, once-daily oral drug and is not approved anywhere.
- It targets alpha-4 beta-7 integrin, a pathway already validated in inflammatory bowel disease, according to Gilead.
- At week 12, 66% responded on 200 mg versus 37% on placebo, a gap of about 29 points by our calculation.
- Gilead reports similar adverse-event rates to placebo and plans a Phase 3 study in 2027.
- Maintenance results are still to come.
What inflammatory bowel disease is
General background: inflammatory bowel disease covers long-lasting conditions in which the digestive tract becomes inflamed. Ulcerative colitis, the subject of SWIFT, affects the large intestine, and the NIDDK page on ulcerative colitis describes it as causing inflammation and sores in the lining. Symptoms can come and go. Treatment aims to calm inflammation and keep the disease in remission.
Why an oral inflammatory bowel disease treatment is attractive
This section is our general framing. A pill taken once a day may be easier for some patients than an injection or an infusion given at a clinic, and may suit people who prefer to treat at home. Whether that advantage is real depends on how well the drug works, how safe it proves over years and how it compares with existing choices, none of which Phase 2 can answer.
How this oral inflammatory bowel disease treatment works
General background, not from the study: alpha-4 beta-7 is a protein on certain white blood cells that helps them travel into the gut lining. Blocking it is intended to reduce the number of those cells reaching the intestine and so lower inflammation there. Gilead says this target is clinically validated in inflammatory bowel disease and that emvistegrast is an oral inhibitor of it, discovered and developed internally.
What the SWIFT study measured
According to Gilead’s statement, SWIFT is a Phase 2, randomised, double-blind, placebo-controlled study in adults aged 18 to 75 with moderately to severely active ulcerative colitis. People were assigned equally to emvistegrast 200 mg, 75 mg, 25 mg or placebo, and 238 took part. The primary endpoint was clinical response at week 12 based on the modified Mayo score, which combines symptom and endoscopy measures. The trial registry entry provides the formal listing.
The oral inflammatory bowel disease treatment results in plain terms
On the 200 mg dose, 39 of 59 people (66%) had a clinical response against 22 of 60 (37%) on placebo. Clinical remission was 31% versus 8%, mucosal healing 24% versus 10% and endoscopic improvement 39% versus 12%. Gilead gives p-values but calls them nominal, meaning they were not adjusted for multiple comparisons. The company did not report efficacy for the 75 mg and 25 mg doses in its statement, so how the benefit changes with dose is unknown.
What the safety numbers say about this oral inflammatory bowel disease treatment
Gilead reports adverse events in 36% of those on emvistegrast and 37% on placebo, with serious adverse events in 4 of 178 people on the drug (2%) and none on placebo, all judged unrelated to the drug. Three people stopped treatment because of side effects. These are short-term findings from a few hundred participants, and a longer, larger programme is needed to understand rarer effects.
Why the placebo response matters
This section is our general explanation. In ulcerative colitis trials, a sizeable share of people on placebo often improve, partly because symptoms fluctuate and partly because patients in a trial are closely monitored. Here 37% of the placebo group met the response definition. The useful figure is therefore the gap between drug and placebo, about 29 percentage points for response and about 23 for clinical remission by our subtraction, and not the 66% on its own.
What Phase 2 can and cannot show about an oral inflammatory bowel disease treatment
Phase 2 studies are designed to find out whether a drug seems to work and which doses to test further. They are not designed to prove that it works or to compare it with other treatments. Many drugs that succeed at this stage do not succeed in larger trials. That is why Gilead’s plan for a Phase 3 monotherapy study in 2027 is the next real test, and why the maintenance data due from SWIFT matter for judging how long benefits last.
What is not disclosed
- Efficacy results for the 75 mg and 25 mg doses.
- Maintenance results through week 52.
- Design and size of the planned Phase 3 study.
- Any comparison with approved treatments.
Risks and caveats on this oral inflammatory bowel disease treatment
- The data come from a company statement and conference presentation.
- P-values are nominal and the placebo response was substantial at 37%.
- Our gap calculation is simple subtraction and not a formal estimate.
- This is news reporting, not medical advice, and patients should talk to their doctors.
In our assessment, emvistegrast is an encouraging early signal for an oral inflammatory bowel disease treatment, but patients and clinicians should wait for maintenance results and Phase 3 before drawing conclusions. See also AstraZeneca Signs AI Drug-Discovery Deal Worth Up to $1.5 Billion With insitro. More in our pharmaceutical coverage.
What to watch next on the oral inflammatory bowel disease treatment
- SWIFT maintenance and extension results.
- Dose data for 75 mg and 25 mg.
- Start of the Phase 3 programme in 2027.
Frequently asked questions
What is emvistegrast?
An investigational, once-daily oral alpha-4 beta-7 integrin inhibitor from Gilead.
How well did it work?
66% of people on 200 mg had a clinical response at week 12 versus 37% on placebo.
When could it be available?
Not known. It is not approved, and Phase 3 is planned to start in 2027.
How we reported this: we relied on Gilead’s statement of 19 October 2026, the trial registry and a public health page. General background and our calculations are labelled. Last updated: 20 October 2026. This article is news reporting and not medical advice.
